Archives

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Cabaletta disavows any obligation to update the information contained in such press releases after the date of their issuance. 

 
09/05/2019
Cabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel
Read More
07/15/2019
Autoimmune Clinical Drug Development Expert, David J. Chang, M.D., M.P.H., Joins Cabaletta Bio as Chief Medical Officer
Read More
04/02/2019
Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to its Board of Directors
Read More
03/06/2019
Cabaletta Bio to Present at the Cowen and Company 39th Annual Healthcare Conference
Read More
02/19/2019
Cabaletta Bio Appoints Experienced Financial Executive, Richard Henriques, to its Board of Directors
Read More
01/23/2019
Cabaletta Bio Appoints Anup Marda as Chief Financial Officer
Read More
01/03/2019
Cabaletta Bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
Read More
01/03/2019
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cell-Mediated Autoimmune Diseases
Read More
12/12/2018
Cell Therapy Industry Pioneer, Gwendolyn Binder, Ph.D., to Join Cabaletta Bio Leadership Team
Read More
11/15/2018
Cabaletta Bio Expands Scientific, Regulatory and Cell Therapy Manufacturing Expertise with Scientific Advisory Board Additions
Read More
11/08/2018
Cabaletta Bio Emerges Out of University of Pennsylvania to Develop CAAR T Cell Technology to Treat B Cell-mediated Autoimmune Diseases
Read More